The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
Abstract
BACKGROUND: Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS: In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogram) less than 6 hours after the onset of ischemic stroke. To favor the selection of patients most likely to benefit from thrombolytic therapy, the eligibility criteria were a perfusion lesion at least 20% greater than the infarct core on computed tomographic (CT) perfusion imaging at baseline and an associated vessel occlusion on CT angiography. The coprimary end points were the proportion of the perfusion lesion that was reperfused at 24 hours on perfusion-weighted magnetic resonance imaging and the extent of clinical improvement at 24 hours as assessed on the National Institutes of Health Stroke Scale (NIHSS, a 42-point scale on which higher scores indicate more severe neurologic deficits). RESULTS: The three treatment groups each comprised 25 patients. The mean (±SD) NIHSS score at baseline for all patients was 14.4±2.6, and the time to treatment was 2.9±0.8 hours. Together, the two tenecteplase groups had greater reperfusion (P=0.004) and clinical improvement (P<0.001) at 24 hours than the alteplase group. There were no significant between-group differences in intracranial bleeding or other serious adverse events. The higher dose of tenecteplase (0.25 mg per kilogram) was superior to the lower dose and to alteplase for all efficacy outcomes, including absence of serious disability at 90 days (in 72% of patients, vs. 40% with alteplase; P=0.02). CONCLUSIONS: Tenecteplase was associated with significantly better reperfusion and clinical outcomes than alteplase in patients with stroke who were selected on the basis of CT perfusion imaging. (Funded by the Australian National Health and Medical Research Council; Australia New Zealand Clinical Trials Registry number, ACTRN12608000466347.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804656 · Cited by 6,684
Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)08020-9 · Cited by 3,662
Self-citationLees, K. R., Bluhmki, E., von Kummer, R., Brott, T. G., Toni, D., Grotta, J. C., Albers, G. W., Kaste, M., Marler, J. R., Hamilton, S. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60491-6 · Cited by 2,184
Self-citationDavis, S. M., Donnan, G. A., Parsons, M. W., Levi, C., Butcher, K. S., Peeters, A., Barber, P. A., Bladin, C., De Silva, D. A., Byrnes, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70044-9 · Cited by 1,052
Self-citationThrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study
Wahlgren, N., Ahmed, N., Dávalos, A., Hacke, W., Millán, M., Muir, K., Roine, R. O., Toni, D., & Lees, K. R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61339-2 · Cited by 569
Acute Stroke Imaging Research Roadmap
Wintermark, M., Albers, G. W., Alexandrov, A. V., Alger, J. R., Bammer, R., Baron, J.-C., Davis, S., Demaerschalk, B. M., Derdeyn, C. P., Donnan, G. A., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.512319 · Cited by 423
Self-citationAcute Stroke Imaging Research Roadmap II
Wintermark, M., Albers, G. W., Broderick, J. P., Demchuk, A. M., Fiebach, J. B., Fiehler, J., Grotta, J. C., Houser, G., Jovin, T. G., Lees, K. R., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.002015 · Cited by 366
Self-citationTanswell, P., Modi, N., Combs, D., & Danays, T. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241150-00001 · Cited by 298
Ahmed, N., Wahlgren, N., Grond, M., Hennerici, M., Lees, K. R., Mikulik, R., Parsons, M., Roine, R. O., Toni, D., & Ringleb, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70165-4 · Cited by 289
Self-citationHaley, E. C., Thompson, J. L. P., Grotta, J. C., Lyden, P. D., Hemmen, T. G., Brown, D. L., Fanale, C., Libman, R., Kwiatkowski, T. G., Llinas, R. H., et al. (2010) · Stroke · doi:10.1161/strokeaha.109.572040 · Cited by 271
Khatri, P., Neff, J., Broderick, J. P., Khoury, J. C., Carrozzella, J., & Tomsick, T. (2005) · Stroke · doi:10.1161/01.str.0000185698.45720.58 · Cited by 235
A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke
Haley, E. C., Lyden, P. D., Johnston, K. C., Hemmen, T. M., & the TNK in Stroke Investigators (2005) · Stroke · doi:10.1161/01.str.0000154872.73240.e9 · Cited by 222
Soares, B. P., Tong, E., Hom, J., Cheng, S.-C., Bredno, J., Boussel, L., Smith, W. S., & Wintermark, M. (2010) · Stroke · doi:10.1161/strokeaha.109.568766 · Cited by 188
Brown, D. L., Johnston, K. C., Wagner, D. P., & Haley, E. C. (2004) · Stroke · doi:10.1161/01.str.0000105396.93273.72 · Cited by 159
Silva, D. A. D., Fink, J., Christensen, S., Ebinger, M., Bladin, C., Levi, C. R., Parsons, M. W., Butcher, K., Barber, P. A., Donnan, G. A., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.543595 · Cited by 149
Self-citationDefining the Extent of Irreversible Brain Ischemia Using Perfusion Computed Tomography
Bivard, A., McElduff, P., Spratt, N. J., Levi, C. R., & Parsons, M. W. (2010) · Cerebrovascular Diseases · doi:10.1159/000321897 · Cited by 133
Self-citationIdentification of the penumbra and infarct core on hyperacute noncontrast and perfusion CT
Parsons, M. W., Pepper, E., Bateman, G. A., Wang, Y., & Levi, C. R. (2007) · Neurology · doi:10.1212/01.wnl.0000256366.86353.ff · Cited by 123
Self-citationParsons, M. W., Miteff, F., Bateman, G. A., Spratt, N. J., Loiselle, A., Attia, J., & Levi, C. R. (2009) · Neurology · doi:10.1212/01.wnl.0000344168.05315.9d · Cited by 116
Self-citation
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2018) · Stroke · doi:10.1161/str.0000000000000158 · Cited by 5,446
Campbell, B. C. V., De Silva, D. A., Macleod, M. R., Coutts, S. B., Schwamm, L. H., Davis, S. M., & Donnan, G. A. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0118-8 · Cited by 1,750
Self-citationA Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
Kidwell, C. S., Jahan, R., Gornbein, J., Alger, J. R., Nenov, V., Ajani, Z., Feng, L., Meyer, B. C., Olson, S., Schwamm, L. H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212793 · Cited by 1,387
Metadata
- Authors
- Parsons, M., Spratt, N., Bivard, A., Campbell, B., Chung, K., Miteff, F., O'Brien, B., Bladin, C., McElduff, P., Allen, C., Bateman, G., Donnan, G., Davis, S., & Levi, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-22
- Volume
- 366
- Issue
- 12
- Pages
- 1099-1107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1972869299
- Cited by
- 680
- References
- 19
- FWCI
- 42.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.